Hypertrophic Cardiomyopathy

Transforming Treatment

Hypertrophic cardiomyopathy, or HCM, is the most common genetic heart disease, occurring in one in 500 people and affecting as many as 700,000 Americans. Due largely to the work of the Hypertrophic Cardiomyopathy Center at the Minneapolis Heart Institute Foundation® (MHIF), HCM has become a treatable and manageable disease. MHIF has achieved substantial advances in diagnosis with cardiac MRI, helping target those patients at greatest risk for sudden death. Gains have also been made in the prevention of sudden death with implantable cardiac defibrillators, as well as advancing and promoting relief of heart failure with surgical myectomy. As a result, it is now possible for those with HCM to have normal life expectancy, often without disability.

World Renowned Leadership

The Minneapolis Heart Institute Foundation HCM Center advises physicians from around the world who are working to disseminate the findings of MHIF’s research. Through more than 850 publications, industry conferences and the HCM Summit, held bi-annually at MHIF, identification, treatment and management of HCM continues to be transformed.